Hepatotoxicity after high‐dose intravenous methylprednisolone in multiple sclerosis patients

Hepatotoxicity is a rare adverse event of methylprednisolone that should be considered in clinical practice. In patients at risk, we propose liver function surveillance, by measuring hepatic enzymes concentration 15–30 days after methylprednisolone administration. Additionally, we propose ACTH, dexa...

Descripción completa

Detalles Bibliográficos
Autores principales: Hidalgo de la Cruz, Milagros, Miranda Acuña, Jahir Andrés, Lozano Ros, Alberto, Vega Catalina, María, Salinero Paniagua, Emilio, Clemente Ricote, Gerardo, De Andrés Frutos, Clara Dionisia, Martínez Ginés, María Luisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538224/
https://www.ncbi.nlm.nih.gov/pubmed/28781825
http://dx.doi.org/10.1002/ccr3.1033
_version_ 1783254323255312384
author Hidalgo de la Cruz, Milagros
Miranda Acuña, Jahir Andrés
Lozano Ros, Alberto
Vega Catalina, María
Salinero Paniagua, Emilio
Clemente Ricote, Gerardo
De Andrés Frutos, Clara Dionisia
Martínez Ginés, María Luisa
author_facet Hidalgo de la Cruz, Milagros
Miranda Acuña, Jahir Andrés
Lozano Ros, Alberto
Vega Catalina, María
Salinero Paniagua, Emilio
Clemente Ricote, Gerardo
De Andrés Frutos, Clara Dionisia
Martínez Ginés, María Luisa
author_sort Hidalgo de la Cruz, Milagros
collection PubMed
description Hepatotoxicity is a rare adverse event of methylprednisolone that should be considered in clinical practice. In patients at risk, we propose liver function surveillance, by measuring hepatic enzymes concentration 15–30 days after methylprednisolone administration. Additionally, we propose ACTH, dexamethasone, or plasma exchange as alternate treatment options for these patients.
format Online
Article
Text
id pubmed-5538224
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-55382242017-08-04 Hepatotoxicity after high‐dose intravenous methylprednisolone in multiple sclerosis patients Hidalgo de la Cruz, Milagros Miranda Acuña, Jahir Andrés Lozano Ros, Alberto Vega Catalina, María Salinero Paniagua, Emilio Clemente Ricote, Gerardo De Andrés Frutos, Clara Dionisia Martínez Ginés, María Luisa Clin Case Rep Case Reports Hepatotoxicity is a rare adverse event of methylprednisolone that should be considered in clinical practice. In patients at risk, we propose liver function surveillance, by measuring hepatic enzymes concentration 15–30 days after methylprednisolone administration. Additionally, we propose ACTH, dexamethasone, or plasma exchange as alternate treatment options for these patients. John Wiley and Sons Inc. 2017-06-09 /pmc/articles/PMC5538224/ /pubmed/28781825 http://dx.doi.org/10.1002/ccr3.1033 Text en © 2017 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Case Reports
Hidalgo de la Cruz, Milagros
Miranda Acuña, Jahir Andrés
Lozano Ros, Alberto
Vega Catalina, María
Salinero Paniagua, Emilio
Clemente Ricote, Gerardo
De Andrés Frutos, Clara Dionisia
Martínez Ginés, María Luisa
Hepatotoxicity after high‐dose intravenous methylprednisolone in multiple sclerosis patients
title Hepatotoxicity after high‐dose intravenous methylprednisolone in multiple sclerosis patients
title_full Hepatotoxicity after high‐dose intravenous methylprednisolone in multiple sclerosis patients
title_fullStr Hepatotoxicity after high‐dose intravenous methylprednisolone in multiple sclerosis patients
title_full_unstemmed Hepatotoxicity after high‐dose intravenous methylprednisolone in multiple sclerosis patients
title_short Hepatotoxicity after high‐dose intravenous methylprednisolone in multiple sclerosis patients
title_sort hepatotoxicity after high‐dose intravenous methylprednisolone in multiple sclerosis patients
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538224/
https://www.ncbi.nlm.nih.gov/pubmed/28781825
http://dx.doi.org/10.1002/ccr3.1033
work_keys_str_mv AT hidalgodelacruzmilagros hepatotoxicityafterhighdoseintravenousmethylprednisoloneinmultiplesclerosispatients
AT mirandaacunajahirandres hepatotoxicityafterhighdoseintravenousmethylprednisoloneinmultiplesclerosispatients
AT lozanorosalberto hepatotoxicityafterhighdoseintravenousmethylprednisoloneinmultiplesclerosispatients
AT vegacatalinamaria hepatotoxicityafterhighdoseintravenousmethylprednisoloneinmultiplesclerosispatients
AT salineropaniaguaemilio hepatotoxicityafterhighdoseintravenousmethylprednisoloneinmultiplesclerosispatients
AT clementericotegerardo hepatotoxicityafterhighdoseintravenousmethylprednisoloneinmultiplesclerosispatients
AT deandresfrutosclaradionisia hepatotoxicityafterhighdoseintravenousmethylprednisoloneinmultiplesclerosispatients
AT martinezginesmarialuisa hepatotoxicityafterhighdoseintravenousmethylprednisoloneinmultiplesclerosispatients

Ejemplares similares